Harbour Biomed signed a multiyear collaboration with Bristol Myers Squibb that includes roughly $90 million up front and potential milestones exceeding $1 billion to discover and develop multispecific antibodies. The deal taps Harbour’s AI‑driven discovery platforms and its Harbour Mice humanized system, expanding a run of strategic partnerships the company completed this year. Harbour emphasized continued investment in generative and AI models for antibody design and said the BMS transaction cements its push into faster multispecific discovery. The arrangement includes early research payments and downstream development and commercialization incentives, signaling Big Pharma’s continued willingness to outsource early discovery to specialized biotech platforms.